JPH11511139A - ヒツジアデノウイルスベクターを用いた遺伝子治療 - Google Patents
ヒツジアデノウイルスベクターを用いた遺伝子治療Info
- Publication number
- JPH11511139A JPH11511139A JP9508755A JP50875597A JPH11511139A JP H11511139 A JPH11511139 A JP H11511139A JP 9508755 A JP9508755 A JP 9508755A JP 50875597 A JP50875597 A JP 50875597A JP H11511139 A JPH11511139 A JP H11511139A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- gene
- human
- adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒト細胞に感染可能なヒツジアデノウイルスのゲノムまたは機能的に同等な 核酸配列またはその一部をコードする核酸配列、およびウイルスベクターが少な くとも一つのヒト患者の細胞に感染し感染された細胞が遺伝子を発現するような 細胞において発現される遺伝子をコードする少なくとも一つの核酸配列を含むDN A分子を含むウイルスベクターを、ヒト患者に投与することを含むヒト患者にお ける遺伝子治療の方法。 2.ヒツジアデノウイルスがOAV287である請求項1にしたがった方法。 3.実質的に細胞内で全くウイルスの複製が起こらない請求項1または2にしたが った方法。 4.実質的に細胞内で全く早期または後期ウイルス遺伝子の発現が起こらない請 求項1または2にしたがった方法。 5.遺伝子がガン遺伝子、腫瘍抑制遺伝子、アンチセンスまたはリボザイムRNA 、酵素をコードする遺伝子、サイトカインまたは他の免疫調節高分子をコードす る遺伝子、組換え抗体をコードする遺伝子、細胞溶解性ペプチドをコードする遺 伝子、ワクチン抗原をコードする遺伝子、体細胞における遺伝的欠陥を相補する 高分子をコードする遺伝子および細胞を死に導くプロセスを触媒する高分子をコ ードする遺伝子より成るグループから選択されたものである請求項1から4のいず れか一つにしたがった方法。 6.プロドラッグの存在下で感染された細胞がプロドラッグを細胞を死に導く毒 生産物に代謝するような、プロドラッグを代謝する酵素を遺伝子がコードする請 求項5にしたがった方法。 7.遺伝子が原核生物のプリンヌクレオチドホスホリラーゼ(PNPアーゼ)をコー ドし、プロドラッグが6-メチル-プリン-2'-デオキシリボヌクレオシド(6MPDR)で ある請求項6にしたがった方法。 8.遺伝子が望ましい標的細胞においてのみ発現するように、遺伝子と意義深く リンクした細胞特異的プロモーターをウイルスベクターが含む請求項1から7のい ずれか一つにしたがった方法。 9.細胞特異的プロモーターがウサギプロバシン、ヒトPSA、PSMA、erbB-2また はCEAプロモーターから成るグループより選択されたものである請求項8にしたが った方法。 10.標的細胞が前立腺または胸部ガン細胞である請求項9にしたがった方法。 11.ウイルスベクターがOAV211である請求項1から10のいずれか一つにしたがっ た方法。 12.ヒツジアデノウイルスベクターが修飾されたアデノウイルスゲノムの一つ以 上のコード領域を持つ請求項1から10のいずれか一つにしたがった方法。 13.修飾がウイルスの改変されたコートタンパク質を引き起こす請求項12にした がった方法。 14.改変されたコートタンパク質が繊維状、ヘキソンおよびペントンベースタン パク質より成るグループから選択されたものである請求項13にしたがった方法。 15.修飾が特異的なヒツジアデノウイルスDNA領域を、他の動物またはヒトアデ ノウイルス由来の同等なコード領域で置換したものを含む請求項12から14のいず れか一つにしたがった方法。 16.修飾が望ましい標的細胞に対して結合特異性を持つベクターを引き起こすよ うな請求項13にしたがった方法。 17.ウイルスベクターがOAV206/Ad5fである請求項12から15のいずれか一つにし たがった方法。 18.ウイルスベクターがOAV206/Ad5pである請求項12から15のいずれか一つにし たがった方法。 19.ウイルスベクターがOAV206/Ad5fおよびOAV206/Ad5p由来の両修飾を運ぶもの である請求項12から15のいずれか一つにしたがった方法。 20.ウイルスベクターが104から1014、好ましくは106から1010のml当たりのプラ ーク形成の濃度で投与される請求項1から19のいずれか一つにしたがった方法。 21.ウイルスベクターが局所的に、経口的にまたは注射により投与される請求項 1から20のいずれか一つにしたがった方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPN4776A AUPN477695A0 (en) | 1995-08-14 | 1995-08-14 | Gene therapy |
AUPN4776 | 1995-08-14 | ||
AU4776 | 1995-08-14 | ||
PCT/AU1996/000518 WO1997006826A1 (en) | 1995-08-14 | 1996-08-14 | Gene therapy using ovine adenoviral vectors |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11511139A true JPH11511139A (ja) | 1999-09-28 |
JP4733795B2 JP4733795B2 (ja) | 2011-07-27 |
Family
ID=3789107
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50875597A Expired - Fee Related JP4733795B2 (ja) | 1995-08-14 | 1996-08-14 | ヒツジアデノウイルスベクターを用いた遺伝子治療 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6020172A (ja) |
EP (1) | EP0851769B1 (ja) |
JP (1) | JP4733795B2 (ja) |
AT (1) | ATE288496T1 (ja) |
AU (2) | AUPN477695A0 (ja) |
CA (1) | CA2229631C (ja) |
DE (1) | DE69634300T2 (ja) |
ES (1) | ES2237772T3 (ja) |
NZ (1) | NZ315295A (ja) |
WO (1) | WO1997006826A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534805A (ja) * | 2000-05-31 | 2003-11-25 | ユニバーシティ オブ サスカチュワン | 変化した親和性を有する改変ウシアデノウイルス |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7037712B2 (en) * | 1994-07-26 | 2006-05-02 | Commonwealth Scientific And Industrial Research Organisation | DNA encoding ovine adenovirus (OAV287) and its use as a viral vector |
FR2723697B1 (fr) * | 1994-08-17 | 1996-09-20 | Rhone Poulenc Rorer Sa | Methode de traitement de la restenose par la therapie genique |
WO2000015823A1 (en) * | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
US6440944B2 (en) | 1998-10-16 | 2002-08-27 | Genvec, Inc. | Methods of administering adenoviral vectors |
AU3590000A (en) * | 1999-02-02 | 2000-08-25 | Trustees Of Columbia University In The City Of New York, The | Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof |
ATE397065T1 (de) * | 1999-03-01 | 2008-06-15 | Commw Scient Ind Res Org | Regulatorische konstrukte, die das intron 3 des prostat-spezifischen membranatigen-gens enthalten |
WO2001011066A1 (de) * | 1999-08-06 | 2001-02-15 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Nicht-humaner adenoviraler vektor für den gentransfer, seine anwendung und seine herstellung |
US7115391B1 (en) | 1999-10-01 | 2006-10-03 | Genovo, Inc. | Production of recombinant AAV using adenovirus comprising AAV rep/cap genes |
DE10006886A1 (de) * | 2000-02-16 | 2001-08-23 | Hepavec Ag Fuer Gentherapie | Nichthumaner helferabhängiger Virusvektor |
AU2001261650A1 (en) * | 2000-05-15 | 2001-11-26 | Geron Corporation | Ovine tissue for xenotransplantation |
EP1301612A2 (en) * | 2000-05-31 | 2003-04-16 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
WO2003072703A2 (en) * | 2002-02-05 | 2003-09-04 | Cornell Research Foundation, Inc. | Adenoviral vector with replication-dependent transgene expression |
AUPS145602A0 (en) * | 2002-03-28 | 2002-05-09 | Commonwealth Scientific And Industrial Research Organisation | Composition and method for killing tumours |
FR2842823A1 (fr) * | 2002-07-25 | 2004-01-30 | Inst Nat Sante Rech Med | Adenovirus modifies pour le ciblage des lymphocytes b |
ATE457716T1 (de) | 2002-12-30 | 2010-03-15 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
WO2005117964A2 (en) | 2004-05-27 | 2005-12-15 | Centocor, Inc. | Cynomolgus prostate specific antigen |
WO2006101503A2 (en) * | 2004-06-15 | 2006-09-28 | Centocor, Inc. | Method for screening agents against human prostate disease |
SI3029144T1 (sl) | 2009-03-02 | 2019-11-29 | Univ California | Tumorsko-selektivni adenovirus E1A in E1B mutanti |
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
MX2019003445A (es) | 2016-09-27 | 2019-09-26 | Epicentrx Inc | Proteinas de fusion inmunomoduladoras. |
WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
SG11202002826VA (en) | 2017-09-27 | 2020-04-29 | Epicentrx Inc | Immunomodulatory fusion proteins |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
EP0667912B1 (fr) * | 1993-07-13 | 2008-07-02 | Centelion | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
US5552311A (en) * | 1993-09-14 | 1996-09-03 | University Of Alabama At Birmingham Research Foundation | Purine nucleoside phosphorylase gene therapy for human malignancy |
US5820868A (en) * | 1993-12-09 | 1998-10-13 | Veterinary Infectious Disease Organization | Recombinant protein production in bovine adenovirus expression vector system |
AUPM710194A0 (en) * | 1994-07-26 | 1994-08-18 | Commonwealth Scientific And Industrial Research Organisation | Virus vector |
AU686844B2 (en) * | 1994-07-26 | 1998-02-12 | Commonwealth Scientific And Industrial Research Organisation | DNA encoding ovine adenovirus (OAV287) and its use as a viral vector |
FR2724945B1 (fr) * | 1994-09-27 | 1996-12-27 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
FR2725726B1 (fr) * | 1994-10-17 | 1997-01-03 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en therapie genique |
FR2726285B1 (fr) * | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
-
1995
- 1995-08-14 AU AUPN4776A patent/AUPN477695A0/en not_active Abandoned
-
1996
- 1996-08-14 NZ NZ315295A patent/NZ315295A/en unknown
- 1996-08-14 EP EP96926972A patent/EP0851769B1/en not_active Expired - Lifetime
- 1996-08-14 JP JP50875597A patent/JP4733795B2/ja not_active Expired - Fee Related
- 1996-08-14 US US09/011,525 patent/US6020172A/en not_active Expired - Lifetime
- 1996-08-14 AT AT96926972T patent/ATE288496T1/de not_active IP Right Cessation
- 1996-08-14 CA CA2229631A patent/CA2229631C/en not_active Expired - Fee Related
- 1996-08-14 AU AU66966/96A patent/AU708870B2/en not_active Ceased
- 1996-08-14 DE DE69634300T patent/DE69634300T2/de not_active Expired - Lifetime
- 1996-08-14 ES ES96926972T patent/ES2237772T3/es not_active Expired - Lifetime
- 1996-08-14 WO PCT/AU1996/000518 patent/WO1997006826A1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003534805A (ja) * | 2000-05-31 | 2003-11-25 | ユニバーシティ オブ サスカチュワン | 変化した親和性を有する改変ウシアデノウイルス |
Also Published As
Publication number | Publication date |
---|---|
EP0851769A1 (en) | 1998-07-08 |
US6020172A (en) | 2000-02-01 |
AUPN477695A0 (en) | 1995-09-07 |
JP4733795B2 (ja) | 2011-07-27 |
CA2229631C (en) | 2011-05-24 |
EP0851769B1 (en) | 2005-02-02 |
EP0851769A4 (en) | 1999-01-07 |
ATE288496T1 (de) | 2005-02-15 |
AU6696696A (en) | 1997-03-12 |
AU708870B2 (en) | 1999-08-12 |
DE69634300T2 (de) | 2005-12-22 |
NZ315295A (en) | 1999-09-29 |
DE69634300D1 (de) | 2005-03-10 |
ES2237772T3 (es) | 2005-08-01 |
WO1997006826A1 (en) | 1997-02-27 |
CA2229631A1 (en) | 1997-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4733795B2 (ja) | ヒツジアデノウイルスベクターを用いた遺伝子治療 | |
US6294377B1 (en) | Adenoviral vectors of canine origin | |
JP3565859B2 (ja) | 改良されたアデノウイルスおよびその使用法 | |
AU745560B2 (en) | Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof | |
RU2536931C2 (ru) | Онколитический аденовирус для лечения рака, его применение и фармацевтическая композиция, содержащая его | |
RU2219241C2 (ru) | Дефектный рекомбинантный аденовирусный вектор (варианты) | |
KR102150027B1 (ko) | 종양 선택적 e1a 및 e1b 돌연변이 | |
EP1767642B1 (en) | Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof | |
US6475480B1 (en) | Use of adenoviral E4 reading frames to improve expression of a gene of interest | |
US11795477B2 (en) | Single cycle replicating adenovirus vectors | |
WO1995026411A2 (en) | Composition and methods for creating syngeneic recombinant virus-producing cells | |
CZ20001791A3 (cs) | Metody snížení výskytu homologních rekombinací, adenovirové vektory a buňky obsahující degektní adenovirus | |
WO1996039036A9 (en) | Composition and methods for creating syngeneic recombinant virus-producing cells | |
WO1996039036A1 (en) | Composition and methods for creating syngeneic recombinant virus-producing cells | |
JPH10506018A (ja) | 不活化IVa2遺伝子を有する欠陥組換えアデノウィルス | |
JP2002330786A (ja) | 抗炎症性ベクター | |
Oualikene et al. | Lack of evidence of phenotypic complementation of E1A/E1B-deleted adenovirus type 5 upon superinfection by wild-type virus in the cotton rat | |
US7264818B2 (en) | BAV packaging regions and E1 transcriptional control regions | |
WO2000050618A1 (fr) | Vecteur viral | |
US20040214162A1 (en) | PAV regions for encapsidation and E1 transcriptional control | |
MXPA00004646A (en) | Adenovirus vectors and method for reducing homologous recombination phenomena |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070515 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070803 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071115 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080606 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080626 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081111 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20081218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090610 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110221 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110425 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140428 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |